Cancer Center Pursues Helium Ion Therapy Platform

Radiation-therapy providers in Houston get a look at a possible next-generation particle option now in early research.

Updated on Nov. 9, 2026 in Healthcare

Bold vector editorial illustration of a compact white radiation therapy unit with a single aperture, standing alone in an empty clinical room under soft daylight.
MD Anderson Cancer Center and P-Cure Ltd. announced a November 8, 2026 alliance to develop a compact proton and helium ion therapy platform, with helium ion work still in early research. AI Illustration. Upload story photo >

The University of Texas MD Anderson Cancer Center and P-Cure Ltd. announced a strategic alliance on November 8, 2026 to develop a compact upright platform delivering both proton and helium ion therapy. For Houston-area healthcare operators, the deal signals a new collaboration between a major cancer center and a radiation-equipment developer whose proton platform is FDA-cleared.

Why it matters

Helium ions are described as an emerging next-generation modality that may offer improved dose conformity, reduced lateral scattering, and enhanced biological effectiveness. The collaboration aims to determine how those characteristics can be translated into better patient outcomes, making it a bet on a treatment category that is not yet in routine clinical use.

The only hard figure in the announcement is its November 8, 2026 date, and no sales, patient-volume, or cost comparators were disclosed. The agreement makes UT MD Anderson eligible for payments tied to clinical milestones and commercial sales, but the source gives no amounts.

The players

University of Texas MD Anderson Cancer Center

A Houston-based cancer center within the University of Texas system, known as one of the largest cancer treatment and research institutions in the United States.

P-Cure Ltd.

A developer of compact upright proton therapy systems whose platform has received FDA clearance.

The details

The alliance will start by evaluating the clinical value, patient benefits, and operational advantages of P-Cure's compact upright proton therapy solution, which is already FDA-cleared. The two parties will also run preclinical and clinical programs on helium ion therapy, covering clinical utility studies, translational research, and technology development. If the platform is built, it would be the first helium particle system in North America.

Timeline

  1. November 8, 2026: MD Anderson and P-Cure announce the strategic alliance.

Market Landscape

Proton therapy already sits in a competitive equipment market where cost, footprint, and clinical evidence drive purchasing decisions. This alliance moves a device developer and a leading cancer center toward a helium ion successor, a segment that has not yet reached routine clinical adoption.

Healthcare operators in the Houston area should track whether the helium ion work moves from preclinical studies toward clinical use, since that determines whether it becomes a purchasing consideration. Operators evaluating radiation-therapy equipment should watch how the FDA-cleared P-Cure platform is positioned as this collaboration develops.

The takeaway

Radiation-oncology operators should note that a major cancer center is now partnering on a helium ion pathway that would follow the current FDA-cleared proton platform. Track future announcements on clinical milestones, since the alliance's economics depend on achieving them.

Further reading

For context on the sector, explore more Healthcare coverage for Houston.

Source note: This article includes information reported by News-Medical.